Givlaari Coupon & Prices
Get notified when Givlaari medication is added to NiceRxGet Started Now
Secure: Your personal and medical information is safe with us
Convenient: We manage the whole process and we’re here to assist you
Ongoing refills: We request your medication refills on your behalf
NiceRx works with your healthcare provider to help you access affordable medications directly from U.S. pharmaceutical companies.
How it works
Get started by filling out the online enrollment application to find out if you are eligible for assistance.
NiceRx verifies your eligibility for medication assistance and notifies you if you are pre-qualified. The pharmaceutical company provides your medication for free, and you only pay our service fee.
We will request documents to be submitted by you and your healthcare provider that are required by the pharmaceutical company to complete your enrollment.
Once approved, the pharmaceutical company typically ships a 90-day supply of medication to your home or healthcare provider’s address. Final acceptance is determined by the pharmaceutical company.
Your monthly Givlaari cost savings if eligible
With our assistance, you could access the Givlaari patient assistance program and obtain your medication for free. We only charge a flat monthly fee of $49 per medication for our services.
Am I eligible for Givlaari patient assistance?
We review each Givlaari enrollment application individually to determine if you are eligible. Each assistance program has its own eligibility criteria and the factors considered by most programs are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for the Givlaari patient assistance program?
Our process makes it as easy as possible to apply for the Givlaari patient assistance program. Begin by completing the enrollment application form on our website. Tell us about any medications that you are taking, including Givlaari, your healthcare provider, your insurance plan, and your household income. This information is required by the pharmaceutical manufacturers who will supply the medication, so it is important to make sure this information is accurate and up to date.
We will review the information that you have provided to determine whether you are eligible for patient assistance. If we can pre-qualify you for assistance, NiceRx will handle the full enrollment process on your behalf. If you are approved by the pharmaceutical company, you will typically start receiving your medication in 6 – 8 weeks.
Is NiceRx a Givlaari coupons provider?
NiceRx is not a Givlaari coupon, Givlaari discount card, or Givlaari copay card provider. We do not offer Givlaari manufacturer coupons, Givlaari discounts, rebates, Givlaari savings cards, trial offers, or free Givlaari samples. We are a service provider that helps eligible individuals access their medication directly from the U.S. pharmaceutical company.
Can NiceRx help me if I have insurance?
NiceRx may be able to help you if:
- You have a high copay or coinsurance responsibility for Givlaari
- Your insurance company will not pay for your Givlaari prescription
- Your healthcare plan does not cover your medication
- You do not have insurance
Please apply online to find out if we can help you.
How much does Givlaari cost without insurance?
Without insurance, Givlaari costs will vary depending on where you buy the medication as prices will vary by retailer. As a guide, Givlaari subcutaneous solution (189 mg/mL) will cost around $40,700 for 1 milliliter.
How much does Givlaari cost with insurance?
The copay for Givlaari will depend on the terms of your healthcare plan. Your healthcare provider or pharmacist will be able to calculate your copay with your current insurance. Contact them to find out more.
What is Givlaari?
Givlaari is an FDA (U.S. Food and Drug Administration) approved medication manufactured by Alnylam Pharmaceuticals, Inc. Givlaari is an aminolevulinate synthase 1-directed small interfering RNA for the treatment of adults with acute hepatic porphyria (AHP).
This approval of Givlaari was based on the results of a clinical trial of 94 patients with acute hepatic porphyria. Patients received a placebo or Givlaari. Givlaari’s performance was measured by the rate of porphyria attacks that needed hospitalizations, urgent health care visits, or an intravenous infusion of hemin at home. Patients who were given Givlaari had 70% fewer porphyria attacks than patients receiving a placebo.
Acute hepatic porphyrias (AHP) includes a family of rare, genetic diseases where there is a defect, or lack of one of the enzymes within the heme biosynthetic pathway in the liver that can result in the accumulation of porphyrins, a heme precursor that can be toxic to the tissues at high levels, and neurotoxic heme intermediates aminolevulinic acid (ALA) and porphobilinogen (PBG). Hepatic porphyrias are comprised of four subtypes which include acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP), which are autosomal dominant disorders, and aminolevulinic acid dehydratase deficiency porphyria (ALAD).
What doses of Givlaari are available?
Givlaari is available in injection form, in the following doses: 189 mg/mL in a single-dose vial.
The recommended dose is 2.5 mg/kg once monthly by subcutaneous injection. The dose is based on a patient’s actual body weight.
For additional information, please see the full prescribing information. Always speak with your healthcare professional about any changes to your dose so they can monitor and evaluate your condition.
Givlaari active ingredients
The active ingredient of Givlaari is givosiran, a double-stranded small interfering RNA that causes the breakdown of the enzyme aminolevulinate synthase 1 (ALAS1) mRNA in hepatocytes through RNA interference. This leads to reduced levels of aminolevulinic acid (ALA) and porphobilinogen (PBG), factors associated with attacks, and other disease manifestations of AHP.
Givlaari side effects
The most common side effects of Givlaari in clinical trials include:
- Injection site reactions
In rare instances, Givlaari can cause more serious side effects. These can include:
- Anaphylactic reaction – if anaphylaxis occurs, discontinue treatment and administer appropriate medical treatment
- Hepatic toxicity – measure liver function at baseline and periodically during treatment. Interrupt or stop treatment for severe or clinically significant transaminase elevations
- Renal toxicity – monitor renal function during treatment
Your doctor will assess the benefits of using Givlaari against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Givlaari to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Givlaari drug interactions
Givlaari can interact with other medications. These include:
- Sensitive CYP1A2 and CYP2D6 Substrates – avoid concomitant use as minimal concentration changes may lead to serious or life-threatening toxicities
This list is not exhaustive and other prescription drugs may interact with Givlaari.
You should not use Givlaari if you:
- Are allergic to the active ingredient givosiran
- Are allergic to any of the other ingredients in Givlaari
Talk to your doctor before using Givlaari if you:
- Are taking any of the medications that could interact with Givlaari
- Are pregnant or are planning to become pregnant
- Are breastfeeding or are planning to breastfeed
Givlaari is the trademark brand name for givosiran manufactured by Alnylam Pharmaceuticals. A generic version of givosiran is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Givlaari savings through NiceRx.
*Qualifying persons may obtain medications directly from patient assistance programs without any out-of-pocket cost (or for less than $49 per medication). However, our monthly flat rate of just $49 per medication spares you the hassle of tracking the different programs and filling out all the required paperwork for each program. Subject to medication availability and acceptance by the pharmaceutical companies. NiceRx is not responsible for any delays or rejection by the pharmaceutical companies.
Enrollees enjoy a full-service solution, as NiceRx assists them and their physicians with the entire process. We prepare all required documents for the physician to sign, help enrollees manage all prescription refills, monitor eligibility criteria, and maintain enrollment.
**If you do not receive medications because you were determined to be ineligible for the prescription assistance by the applicable pharmaceutical companies and you have a letter of denial, we will refund any fees you paid toward medications for which you did not qualify to receive prescription assistance (“Refund”).
To receive a refund, you must send the letter of denial to us by fax to 888-517-7444, or by e-mail to [email protected] within 30 days of your receipt of such letter. The Refund is your sole and exclusive remedy for any fees you may wish to dispute.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.